Unjha Formulations

Unjha Formulations P/B

The P/B (Price-to-Book Ratio) of Unjha Formulations (531762.BO) as of Nov 17, 2026 is 2.69. In the previous year, P/B (Price-to-Book Ratio) was 3.29 — a change of -18.34% (lower).

P/B

2.69

YoY

-18.34%

Last updated:

P/B (Price-to-Book Ratio) of Unjha Formulations is 2026 2.69 . P/B (Price-to-Book Ratio) of Unjha Formulations was 2025 3.29 . It decreases by -18.34% lower compared to the previous year.

The Unjha Formulations P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
6.85 INR
Jan 1, 2020
5.69 INR
Jan 1, 2021
5.38 INR
Jan 1, 2022
4.21 INR
Jan 1, 2023
4.21 INR
Jan 1, 2024
3.78 INR
Jan 1, 2025
3.29 INR
Jan 1, 2026
2.69 INR
The Unjha Formulations P/B history
YEARP/BYoY
2.69-18.34%
3.29-12.98%
3.78-10.17%
4.21-0.00%
4.21-21.80%
5.38-5.40%
5.69-16.99%
6.85-19.93%
8.56-21.77%
10.94-31.32%
15.93-39.70%
26.42-44.47%
47.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Unjha Formulations Stock analysis

What does Unjha Formulations do? Unjha Formulations Ltd. generates revenue through the manufacturing and export of Ayurvedic products, primarily targeting international markets. The company's key products include Fibron SF Powder, Albendazole Bolus, and Fibermate, which are isabgol-based formulations. Anchor Sat-Isabgol, available in 50g, 100g, 200g, and 400g sizes, is a flagship product, while Fibron and Fibron SF (Sugar Free) come in 100g and 300g packages. The firm focuses on export markets for its veterinary medicinal formulations not for human use, alongside its Ayurvedic powder and tablet lines. The company's revenue streams are derived from the sale of Fibron SF Powder, Albendazole Bolus, and Fibermate to international buyers seeking Ayurvedic and veterinary products. Anchor Sat-Isabgol is sold in multiple sizes, catering to consumer demand for isabgol-based health supplements. Unjha Formulations Ltd. also produces Small Volume Ayurvedic Isabgol powder, which is exported globally. The primary customers are international importers and distributors specializing in Ayurvedic and veterinary medicinal products. Export markets drive the company's business model, with Fibron SF Powder and Fibron being key revenue contributors. The firm's veterinary medicinal formulation not for human use, including Albendazole Bolus, targets agricultural and livestock sectors. Anchor Sat-Isabgol's availability in various sizes ensures broad market reach, while the company's focus on isabgol-based formulations aligns with global demand for natural health products. Unjha Formulations is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Unjha Formulations stock

P/B (Price-to-Book Ratio) of Unjha Formulations is 2.69 in 2026.

P/B (Price-to-Book Ratio) of Unjha Formulations changed from 3.29 to 2.69, representing a -18.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Unjha Formulations since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Unjha Formulations with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Unjha Formulations

All Key Metrics — Unjha Formulations